These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 26893184)

  • 1. Evolution of strategies to improve preclinical cardiac safety testing.
    Gintant G; Sager PT; Stockbridge N
    Nat Rev Drug Discov; 2016 Jul; 15(7):457-71. PubMed ID: 26893184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
    Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
    Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers.
    Huo J; Kamalakar A; Yang X; Word B; Stockbridge N; Lyn-Cook B; Pang L
    Toxicol Sci; 2017 Mar; 156(1):25-38. PubMed ID: 28031415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
    Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays.
    Harris K; Aylott M; Cui Y; Louttit JB; McMahon NC; Sridhar A
    Toxicol Sci; 2013 Aug; 134(2):412-26. PubMed ID: 23690542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human-induced pluripotent stem cell-derived cardiomyocytes from cardiac progenitor cells: effects of selective ion channel blockade.
    Altomare C; Pianezzi E; Cervio E; Bolis S; Biemmi V; Benzoni P; Camici GG; Moccetti T; Barile L; Vassalli G
    Europace; 2016 Dec; 18(suppl 4):iv67-iv76. PubMed ID: 28011833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
    Satsuka A; Kanda Y
    Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity screening: a review of rapid-throughput in vitro approaches.
    Li X; Zhang R; Zhao B; Lossin C; Cao Z
    Arch Toxicol; 2016 Aug; 90(8):1803-16. PubMed ID: 26676948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
    Clements M; Millar V; Williams AS; Kalinka S
    Toxicol Sci; 2015 Nov; 148(1):241-60. PubMed ID: 26259608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi).
    Takasuna K; Kazusa K; Hayakawa T
    Curr Pharm Biotechnol; 2020; 21(9):829-841. PubMed ID: 31749424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Cardiotoxicity With Stem Cell-based Strategies.
    Stella Stoter AM; Hirt MN; Stenzig J; Weinberger F
    Clin Ther; 2020 Oct; 42(10):1892-1910. PubMed ID: 32938533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association.
    Gintant G; Burridge P; Gepstein L; Harding S; Herron T; Hong C; Jalife J; Wu JC
    Circ Res; 2019 Oct; 125(10):e75-e92. PubMed ID: 31533542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of appropriate stage of human-induced pluripotent stem cell-derived cardiomyocytes for drug screening and pharmacological evaluation in vitro.
    Shinozawa T; Imahashi K; Sawada H; Furukawa H; Takami K
    J Biomol Screen; 2012 Oct; 17(9):1192-203. PubMed ID: 22706346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manipulation-free cultures of human iPSC-derived cardiomyocytes offer a novel screening method for cardiotoxicity.
    Rajasingh S; Isai DG; Samanta S; Zhou ZG; Dawn B; Kinsey WH; Czirok A; Rajasingh J
    Acta Pharmacol Sin; 2018 Oct; 39(10):1590-1603. PubMed ID: 29620051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
    Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Heart Cardiomyocytes in Drug Discovery and Research: New Opportunities in Translational Sciences.
    Abi-Gerges N; Miller PE; Ghetti A
    Curr Pharm Biotechnol; 2020; 21(9):787-806. PubMed ID: 31820682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of dual-cardiotoxicity evaluation method based on analysis of field potential and contractile force of human iPSC-derived cardiomyocytes / multielectrode assay platform.
    Lee SG; Kim J; Oh MS; Ryu B; Kang KR; Baek J; Lee JM; Choi SO; Kim CY; Chung HM
    Biochem Biophys Res Commun; 2021 May; 555():67-73. PubMed ID: 33813278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.